Back to Search Start Over

Cell lines generated from a chronic lymphocytic leukemia mouse model exhibit constitutive Btk and Akt signaling.

Authors :
Singh SP
Pillai SY
de Bruijn MJW
Stadhouders R
Corneth OBJ
van den Ham HJ
Muggen A
van IJcken W
Slinger E
Kuil A
Spaargaren M
Kater AP
Langerak AW
Hendriks RW
Source :
Oncotarget [Oncotarget] 2017 May 26; Vol. 8 (42), pp. 71981-71995. Date of Electronic Publication: 2017 May 26 (Print Publication: 2017).
Publication Year :
2017

Abstract

Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of mature CD5 <superscript>+</superscript> B cells in blood. Spontaneous apoptosis of CLL cells in vitro has hampered in-depth investigation of CLL pathogenesis. Here we describe the generation of three monoclonal mouse cell lines, EMC2, EMC4 and EMC6, from the IgH.TEμ CLL mouse model based on sporadic expression of SV40 large T antigen. The cell lines exhibit a stable CD5 <superscript>+</superscript> CD43 <superscript>+</superscript> IgM <superscript>+</superscript> CD19 <superscript>+</superscript> CLL phenotype in culture and can be adoptively transferred into Rag1 <superscript>-/-</superscript> mice. RNA-seq analysis revealed only minor differences between the cell lines and their primary tumors and suggested that NF-κB and mTOR signaling pathways were involved in cell line outgrowth. In vitro survival and proliferation was dependent on constitutive phosphorylation of Bruton's tyrosine kinase (Btk) at Y551/Y223, and Akt(S473). Treatment of the cell lines with small molecule inhibitors specific for Btk (ibrutinib) or PI3K (idelalisib), which is upstream of Akt, resulted in reduced viability, proliferation and fibronectin-dependent cell adhesion. Treatment of cell line-engrafted Rag1 <superscript>-/-</superscript> mice with ibrutinib was associated with transient lymphocytosis, reduced splenomegaly and increased overall survival. Thus, by generating stable cell lines we established a novel platform for in vitro and in vivo investigation of CLL signal transduction and treatment modalities.<br />Competing Interests: CONFLICTS OF INTEREST The authors declare no conflicts of interest.

Details

Language :
English
ISSN :
1949-2553
Volume :
8
Issue :
42
Database :
MEDLINE
Journal :
Oncotarget
Publication Type :
Academic Journal
Accession number :
29069762
Full Text :
https://doi.org/10.18632/oncotarget.18234